225 related articles for article (PubMed ID: 26800397)
1. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.
Zeng LP; Hu ZM; Li K; Xia K
J Cell Mol Med; 2016 Mar; 20(3):559-67. PubMed ID: 26800397
[TBL] [Abstract][Full Text] [Related]
2. miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
Lei Y; Li B; Tong S; Qi L; Hu X; Cui Y; Li Z; He W; Zu X; Wang Z; Chen M
PLoS One; 2015; 10(2):e0117809. PubMed ID: 25658842
[TBL] [Abstract][Full Text] [Related]
3. microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARĪ³ in esophageal cancer.
Wu K; Hu Y; Yan K; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
J Cell Physiol; 2020 Feb; 235(2):1247-1258. PubMed ID: 31267531
[TBL] [Abstract][Full Text] [Related]
4. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
5. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
[TBL] [Abstract][Full Text] [Related]
6. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
7. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
10. Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy.
Su J; Xu Y; Zhou L; Yu HM; Kang JS; Liu N; Quan CS; Sun LK
Anat Rec (Hoboken); 2013 Apr; 296(4):595-603. PubMed ID: 23408563
[TBL] [Abstract][Full Text] [Related]
11. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways.
Noguchi S; Yasui Y; Iwasaki J; Kumazaki M; Yamada N; Naito S; Akao Y
Cancer Lett; 2013 Jan; 328(2):353-61. PubMed ID: 23104321
[TBL] [Abstract][Full Text] [Related]
12. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.
Zhou S; Huang Q; Zheng S; Lin K; You J; Zhang X
Tumour Biol; 2016 May; 37(5):6837-45. PubMed ID: 26662313
[TBL] [Abstract][Full Text] [Related]
13. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
[TBL] [Abstract][Full Text] [Related]
14. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1.
Li Q; Xia X; Ji J; Ma J; Tao L; Mo L; Chen W
Oncotarget; 2017 May; 8(20):33621-33630. PubMed ID: 28422725
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer.
Li Y; Shan Z; Liu C; Yang D; Wu J; Men C; Xu Y
Biochemistry (Mosc); 2017 Apr; 82(4):474-482. PubMed ID: 28371605
[TBL] [Abstract][Full Text] [Related]
16. miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells.
Liang WL; Cao J; Xu B; Yang P; Shen F; Sun Z; Li WL; Wang Q; Liu F
Biomed Pharmacother; 2015 May; 72():119-24. PubMed ID: 26054685
[TBL] [Abstract][Full Text] [Related]
17. MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR.
Yu Z; Li N; Jiang K; Zhang N; Yao LL
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5867-5873. PubMed ID: 30280766
[TBL] [Abstract][Full Text] [Related]
18. miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer.
Lin J; Lin Y; Fan L; Kuang W; Zheng L; Wu J; Shang P; Wang Q; Tan J
Biochem Biophys Res Commun; 2016 Apr; 473(2):382-7. PubMed ID: 26946357
[TBL] [Abstract][Full Text] [Related]
19. Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.
Mu DW; Guo HQ; Zhou GB; Li JY; Su B
Int J Clin Exp Pathol; 2015; 8(11):13864-70. PubMed ID: 26823699
[TBL] [Abstract][Full Text] [Related]
20. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
